In case you missed some of our live coverage of the National Kidney Foundation Spring Clinical Meetings last month, Healio/Nephrology has compiled five of the most popular stories.
These included a presentation about the revised Kidney Disease Outcomes Quality Initiative guidelines, the necessity of a national home dialysis strategy and a study that found an exercise program for older patients with chronic kidney disease was effective.
Other highlights included research that determined weight gain in kidney transplant recipients is often linked to the stress that accompanies living in underserved communities and phase 2 results from the AMBER trial that found combining spironolactone therapy with patiromer safely reduced blood pressure in patients with CKD.
Revised KDOQI guidelines call for matching vascular access type with modality choice, patient goals
BOSTON — Revisions to guidelines for vascular access placement in the patient with ESKD – the first in 10 years – place a greater emphasis on matching patients’ care plans and modality options with the access choice. Read more.
A national home dialysis strategy is needed but will be challenging and multifactorial
BOSTON — When thinking aspirationally about a national strategy for home dialysis, the kidney community should consider the priorities of patients, according to an expert here at the National Kidney Foundation Spring Clinical Meetings. Read more.
Exercise program in older patients with advanced CKD seen as feasible, safe
BOSTON — A supervised exercise training program can be an option for older sedentary adults with CKD stages 3b to 4 and showed adherence comparable to long-term exercise programs of healthier older adults. Read more.
Low socioeconomic status and associated stress contribute to weight gain in kidney transplant recipients
BOSTON — Kidney transplant recipients from underserved communities have limited access to healthy foods and high levels of stress and anxiety, which contribute to a likelihood of weight gain post-transplant. Read more.
AMBER trial: Spironolactone with patiromer safely reduces BP in patients with CKD, resistant hypertension
BOSTON — Combining spironolactone therapy with patiromer may allow patients with CKD and resistant hypertension to safely manage their blood pressure without increasing their risk for developing hyperkalemia, according to phase 2 results from the AMBER trial, presented at the National Kidney Foundation Spring Clinical Meetings. Read more.